Bearish count just to show that I know it's possible
Green boxes for green abc
Blue boxes for blue ABC
I can update this into less scenarios and clean up the future price targets IF and WHEN wave B finishes. I don't know where that will be but if the price data confirms it, it'll give tagets for C before lift off.
A mediocre wave 3, 1:1 ratio of wave 1 -
I don't see this scenario playing out but regardless selling at 85-86 to buy back in a big dip would be a good idea
Experts and analysts are falling over one another to upgrade GBT so it is no surprise it has had a beautiful run in 2019. Don't worry if you have missed out this is just the start, as commercialization becomes a reality.
The company's under-the-radar licensing of inclacumab "completes the package", making Global Blood Therapeutics a force to reckon with in sickle...
Continuing from previous post... It is safe to assume the area of 49-50 has strong support due to multiple down days bouncing back off those price levels. We finally broke through resistance at 53-54 levels but risk a gap-fill. Any dips below 53 should be momentary and needs to close above to continue upwards.
Using fib-extensions from Mar 6 and Mar 28, I've...
Retraced from highs and lows within the last 12 months and found the current price to be within an important zone... Above 50 is always a good sign and will eventually push if it holds. Line below price is it's support level. Under would reverse this.
GBT: Global Blood Therapeutics, Inc.
2018-12-03 10:00:00
GBT Announces Positive 24-week Results from Phase 3 HOPE Study Demonstrating Clinically and Statistically Significant Improvements in Hemoglobin and Clinical Measures of Hemolysis and a Favorable Safety Profile
We have a gap down trapping this bear flag. I like it to the first target, but if it really breaks down it's going to target 2 which is the 100MA on the weekly
Global Blood Therapeutics’ candidate (Voxelotor) has a lot of potential for SCD.
There are a lot of articles on Sickle Cell Disease (SCD) which I strongly invite you to read.
From a Technical Analysis point of view, I like what I see in GBT's chart.
For me, the stock ended an a-b-c correction and is now preparing to move forward.
Confirmation is needed but...
I'll start this off with I have 0 positions in this company - only came across the ticker doing intra-day scans. I'll start with the most recent huge volume - peeped the news - apparently homeguy H.C Wainwright gives a $120 price target. Was trading $38.70 day before so I'm thinking this mf (since it's a biotech) got FDA approval on high blood pressure treatment...
This stock has a great outlook in regards to bullish fundamentals. I chose this demand level and my order is as follows:
Entry : 18.63
Stop : 16.10
I am looking to hold this for a month or so with exit orders:
Target 1 : 20.17
Target 2 : 21.70
Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD). The Company is evaluating GBT440 in SCD in a Phase III clinical trial of GBT440 in adult and adolescent patients with SCD. GBT440 inhibits abnormal hemoglobin polymerization, the underlying mechanism of RBC sickling. The Company is also engaged in other research and development activities targeted towards hereditary angioedema (HAE). The Company's GBT440 is an investigational drug that increases hemoglobin's affinity for oxygen by binding to the alpha-chain of hemoglobin. GBT440 has been observed to keep a proportion of sickle hemoglobin (HbS), in its oxygenated state, where it cannot participate in polymerization.
This website uses cookies to ensure you get the best experience on our website. To learn more about cookies, including how to control cookies, please read our Cookies Policy.
GBT
